ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

MLA

Donawho, Cherrie K., et al. “ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor That Potentiates DNA-Damaging Agents in Preclinical Tumor Models.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 13, no. 9, May 2007, pp. 2728–37. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-06-3039.

APA

Donawho, C. K., Luo, Y., Luo, Y., Penning, T. D., Bauch, J. L., Bouska, J. J., Bontcheva-Diaz, V. D., Cox, B. F., DeWeese, T. L., Dillehay, L. E., Ferguson, D. C., Ghoreishi-Haack, N. S., Grimm, D. R., Guan, R., Han, E. K., Holley-Shanks, R. R., Hristov, B., Idler, K. B., Jarvis, K., … Frost, D. J. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 13(9), 2728–2737. https://doi.org/10.1158/1078-0432.CCR-06-3039

Chicago

Donawho, Cherrie K, Yan Luo, Yanping Luo, Thomas D Penning, Joy L Bauch, Jennifer J Bouska, Velitchka D Bontcheva-Diaz, et al. 2007. “ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor That Potentiates DNA-Damaging Agents in Preclinical Tumor Models.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 13 (9): 2728–37. doi:10.1158/1078-0432.CCR-06-3039.